Press coverage about Strongbridge Biopharma (NASDAQ:SBBP) has trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Strongbridge Biopharma earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 44.7065434265582 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
A number of equities research analysts recently weighed in on SBBP shares. Zacks Investment Research cut shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, November 22nd. BidaskClub upgraded shares of Strongbridge Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Thursday. ValuEngine cut Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Cantor Fitzgerald initiated coverage on Strongbridge Biopharma in a research note on Tuesday, December 5th. They issued a “buy” rating and a $14.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Strongbridge Biopharma in a research note on Wednesday, November 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Strongbridge Biopharma currently has an average rating of “Buy” and a consensus target price of $12.81.
Strongbridge Biopharma (NASDAQ SBBP) traded up $0.10 on Monday, reaching $8.00. The company had a trading volume of 265,400 shares, compared to its average volume of 218,322. Strongbridge Biopharma has a 12-month low of $2.10 and a 12-month high of $8.85. The company has a current ratio of 4.70, a quick ratio of 4.61 and a debt-to-equity ratio of -1.89. The firm has a market cap of $286.50, a price-to-earnings ratio of -2.35 and a beta of 2.60.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Strongbridge Biopharma (SBBP) Stock Price” was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://baseballnewssource.com/markets/strongbridge-biopharma-sbbp-earns-media-impact-score-of-0-22/1817880.html.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.